Recruiting

Donor Milk

Sponsor:

University of Calgary

Code:

NCT06177184

Conditions

Microbial Colonization

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Accepted

Interventions

Donor Human Milk - Nutritional Replacement

Study Details

Brief summary:

The objective of this novel study is to establish proof of concept using a pilot randomized controlled trial to determine the effect of DHM compared to formula supplementation on the microbiome in full-term infants who are born via caesarean section and require supplementation. Secondarily, this study aims to compare the infant health outcomes of sleep and growth between groups to assess if these outcomes are mediated by infant feeding type or potential differences in microbial signatures. Finally, this study will compare maternal outcomes of depression, anger, breastfeeding self-efficacy and breastfeeding rates between groups.

The infant gut microbiome plays a critical role in the developing immune, neurologic, and endocrine systems. Yet, most infants experience early life disruptions (ELDs) to their microbiome that have potential long-term health and development impacts. A major source of disruption is caesarean section (c-section) delivery because the infant is born surgically and is not exposed to important commensal bacteria required to establish the infant microbiome. Currently in Canada, over 28% of infants are born via c-section.

Exclusive breastfeeding can improve gut microbiota composition in infants who are born via c-section. However, approximately 60% of infants born via c-section require formula supplementation in their first week of life. Evidence indicates that even one bottle of formula can further disrupt the gut microbiome.

Donor human milk (DHM) is a superior alternative to formula when supplementation is required as its biotic properties minimize perturbations to the infant gut microbiome and may help to repair the microbiome in infants who experience ELDs. Yet, while DHM is well researched in preterm populations, evidence on the impact of DHM as a therapeutic intervention on the full-term infant gut microbiome is lacking.

The hypothesis of this study is: that replacing formula with DHM supplementation will minimize gut microbiome dysbiosis and foster homeostasis following supplementation. In addition, it is hypothesized that improved homeostasis will promote improved sleep and growth outcomes in participant infants. Finally, mothers whose infants receive DHM will have lower depression and anger scores and higher breastfeeding self-efficacy and exclusive breastfeeding rates compared to mothers whose infants receive formula.

Conditions

Microbial Colonization

Study ID

NCT06177184

Start date

Oct 1, 2024

Status verified date

Mar, 2025

Completion date

Dec 31, 2027

Anticipated

Primary completion date

May 1, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Gestation greater than 37 weeks gestation (full-term)
  • Caesarean Section delivery
  • Intending to breastfeed
  • Consent for infant to receive DHM
  • Working understanding (proficient in reading and understanding) of English
  • Mother has provided signed and dated informed consent and authorization to use protected health information, as required by national and local regulations.
  • In the investigator's opinion, the subject mother understands and can comply with protocol requirements, instructions, and protocol-stated restrictions, and is likely to complete the study as planned.

Exclusion Criteria:

  • Diagnosed with clinically significant major congenital malformation that will interfere with breastfeeding or growth
  • No intention to breastfeed

Study Design

Enrollment

90 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Donor Human Milk

Infants randomized to the intervention group will receive DHM each time supplementation is required for the first 7 days of life.

no intervention: Standard Care (Infant Formula)

Infants randomized to the standard care group will receive formula each time supplementation is required for the first 7 days of life.

Interventions

Donor Human Milk - Nutritional Replacement

All DHM in North America is pasteurized and provided through certified milk banks regulated by the Human Milk Banking Association of North America. DHM for this study will be obtained from the NorthernStar Mothers Milk Bank (NMMB). The milk is pasteurized and rigorously tested according to Human Milk Banking Association of North America guidelines. In Canada, DHM is categorized as food or nutritional therapy and the milk bank is monitored and certified by the Canadian Food Inspection Agency. The product used for this study will be the same product that is provided to other hospital units (mainly the neonatal intensive care units) in Alberta and around Canada. The product will not be modified or tampered with in any way.

Primary outcome measure

  • Infant gut microbiome - shallow shotgun metagenomics (RA) [ Time Frame: one week postpartum ]
  • Infant gut microbiome - shallow shotgun metagenomics (RA) [ Time Frame: three months postpartum ]
  • Infant gut microbiome - shallow shotgun metagenomics (RA) [ Time Frame: six months postpartum ]
  • Infant gut microbiome - shallow shotgun metagenomics (alpha diversity) [ Time Frame: one week postpartum ]
  • Infant gut microbiome - shallow shotgun metagenomics (alpha diversity) [ Time Frame: 3 months postpartum ]
  • Infant gut microbiome - shallow shotgun metagenomics (alpha diversity) [ Time Frame: six months postpartum ]
  • Infant gut microbiome - shallow shotgun metagenomics (beta diversity) [ Time Frame: one week postpartum ]
  • Infant gut microbiome - shallow shotgun metagenomics (beta diversity) [ Time Frame: three months postpartum ]
  • Infant gut microbiome - shallow shotgun metagenomics (beta diversity) [ Time Frame: six months postpartum ]

Central Contacts and Locations

Central contacts

Locations

Rockeyview General Hospital

Recruiting

Calgary, Alberta, Canada, T2V1P9

Contacts

Principal Investigator:

Meredith Brockway, PhD, RN

More Information

Sponsor

University of Calgary

Last update posted

Feb 20, 2026

Last verified

Mar, 2025

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of Calgary on 2026-02-20.